Stockscreener 앱 받기
9.78
6.19%
0.57
Vir Biotechnology Inc 주식(VIR)의 최신 뉴스
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership - Stocktwits
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) director restructures 16,000-share holding with Alta Partners fund - Stock Titan
Equities Analysts Offer Predictions for VIR Q3 Earnings - marketbeat.com
Vir Biotechnology: Astellas Deal Pushes Cash Above $1 Billion And Extends Runway Into Second Half Of 2028 - Pulse 2.0
Vir Biotechnology (NASDAQ:VIR): What’s Driving Fresh Attention? - Kalkine Media
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
H.C. Wainwright reiterates Vir Biotechnology stock rating on trial progress By Investing.com - Investing.com Canada
Vir Biotechnology Inc (VIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vir Biotechnology (VIR) Receives a Buy from Bank of America Securities - The Globe and Mail
What Vir Biotechnology (VIR)'s Profit Swing But Earnings Miss Means For Shareholders - simplywall.st
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30 - Moomoo
Vir Biotechnology (VIR): State Street discloses 9.96M-share, 5.9% ownership position - Stock Titan
Understanding Momentum Shifts in (VIR) - Stock Traders Daily
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21, Implies 140% Upside - TradingView
Vir Biotechnology Inc (VIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vir Biotechnology, Inc. (VIR) Stock Analysis: Unpacking a 140% Potential Upside for Investors - DirectorsTalk Interviews
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.11, Implies 132% Upside - TradingView
Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
VIR Looks 63.2% Undervalued on GF Value™ - GuruFocus
Vir Biotechnology Q2 Earnings Call Highlights - MarketBeat
Vir Biotechnology, Inc. Stock 12‑Month Price Target Cut to $21.33, Implies 134% Upside - TradingView
VIR SWOT Analysis: Financial Resilience Amidst Clinical Challenges Revealed in 10-Q Filing - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: - GuruFocus
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Jumps 10% on Q2 Beat and Astellas Collaboration - ChartMill
VIR Looks 62.9% Undervalued on GF Value™ Despite Unprofitable St - GuruFocus
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates - Yahoo Finance
Earnings call transcript: Vir Biotechnology jumps on q2 2026 cash and data gains - Investing.com
Vir Biotechnology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Vir Biotechnology Inc (VIR) Undervalued After Q2 Earnings? EP - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS - MarketBeat
Vir Biotechnology Q2 2026 slides: hepatitis delta, oncology gains - Investing.com
Vir Biotechnology (VIR) Releases Q2 2026 Earnings: Revenue and EPS Beat Estimates - Quiver Quantitative
Vir Biotechnology Inc. (VIR) Tops Q2 EPS by 14c - StreetInsider
Vir Biotechnology 2Q 2026: Revenue $238.95M, Net income $80.08M, EPS $0.47— 10-Q Summary - TradingView
Vir Biotechnology (NASDAQ: VIR) swings to profit on $239.3M Astellas deal - Stock Titan
Earnings Flash (VIR) Vir Biotechnology, Inc. Reports Q2 Revenue $238.9M - marketscreener.com
Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment - TradingView
Vir Biotechnology posts $238.9M Q2 revenue, $80.1M net income; $1.01B cash runway into H2 2028 - TradingView
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Investors brace for Vir Biotech earnings amid turnaround bid By Investing.com - Investing.com Nigeria
Renaissance Technologies LLC Increases Stake in Vir Biotechnology, Inc. $VIR - MarketBeat
Earnings To Watch: Vir Biotechnology Inc (VIR) Q2 2026 -- GF Value Sees 175% Upside - Yahoo Finance
Public Employees Retirement System of Ohio Acquires Shares of 112,700 Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology Inc expected to post earnings of 33 cents a shareEarnings Preview - TradingView
950,000 Shares in Vir Biotechnology, Inc. $VIR Bought by Avidity Partners Management LP - MarketBeat
Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition - Yahoo Finance
1.21%
1.07%
자본화:
|
볼륨(24시간):